📦 At-home kits now available.Order your kit →
Resource
Beginner
General

Resia Pretorius Microclots: Who Is Behind the Research?

Tim Ottowitz Published 7 min read

Short answer

The research on fibrin amyloid microclots comes mainly from Prof Etheresia "Resia" Pretorius at Stellenbosch University and Prof Douglas Kell at the University of Liverpool, with clinician co-authors such as Dr Jaco Laubscher of Mediclinic Stellenbosch. Their papers on amyloid-like fibrin clotting date from 2016. Cochrane reviewers and other haematologists dispute what the particles mean for Long COVID.

Illustration related to amyloid microclot research

Key takeaways

  • 1Pretorius and Kell began publishing on amyloid-like fibrin clotting in 2016, before COVID-19.
  • 2The Long COVID microclot papers are small observational studies, typically with tens of participants.
  • 3A Liverpool group led by Schofield and Toh reported microclots in ICU patients, a separate line of work.
  • 4A 2023 Cochrane review found the laboratory evidence insufficient to link the particles to Long COVID.
  • 5Pretorius is named as a director of Biocode Technologies, a microclot-testing spin-out, in a 2023 paper's competing-interest statement.

Fibrin amyloid microclot research comes mainly from Prof Resia Pretorius (Stellenbosch University, South Africa) and Prof Douglas Kell (University of Liverpool, UK), working with clinicians and students. This page lists who they are, who co-authored the key papers, what each paper reported and who disagrees. Everything here comes from the papers and university or ORCID profiles linked below.

Who is Resia Pretorius?

Etheresia "Resia" Pretorius is a Distinguished Professor in Physiological Sciences at Stellenbosch University. Her ORCID record and a 2025 profile on The Conversation list her in that post. The profile adds that she is an Honorary Professor at the University of Liverpool and that her work covers how inflammatory molecules interact with clotting proteins, platelets and blood cells.

Her 2021 Long COVID paper lists her under the Department of Physiological Sciences at Stellenbosch. The 2023 Heliyon paper's competing-interest statement names her as a director of Biocode Technologies, a company that offers microclot testing. That's a disclosure, not a criticism, and it's worth knowing when you read the papers.

Who is Douglas Kell?

Douglas Kell is Research Chair in Systems Biology at the University of Liverpool. His university profile says he studied biochemistry at Oxford, later worked at Aberystwyth and Manchester, and came to Liverpool in December 2018. He describes himself as a systems biologist. He is a co-author on most of the papers in the table below.

Who are the clinician collaborators?

The 2022 Biochemical Journal review lists its authors as Kell (University of Liverpool), Dr Jaco Laubscher (Mediclinic Stellenbosch) and Pretorius. Laubscher is also an author on the 2020, 2021 and 2025 papers below. Biocode's website lists a microclot testing centre at Mediclinic Stellenbosch under Dr Jaco Laubscher.

Other co-authors named in affiliations include Mare Vlok, who works in mass spectrometry at Stellenbosch University, and Dr Asad Khan of Manchester University Hospitals, who appears on the 2023 and 2024 papers. The 2025 NETs paper was led by Alain Thierry's group at the Montpellier Cancer Research Institute, with Stellenbosch co-authors, Laubscher, Kell and Pretorius.

What did each key paper report?

YearPaperJournalWhat it reportedStudy type and size
2016Pretorius et al., LPS and anomalous clottingJ R Soc InterfaceTiny amounts of bacterial LPS added to healthy donors' blood and plasma changed fibrin fibres into an amyloid-like formLab study, healthy donor blood and plasma
2017Kell and Pretorius, "Proteins behaving badly"Prog Biophys Mol BiolArgued that anomalous fibrin in several diseases amounts to amyloidogenesisReview
2017Pretorius et al., type 2 diabetesCardiovasc DiabetolPlasma clotting in type 2 diabetes was amyloid in nature by Thioflavin T and Amytracker stainsLab study, 33 with T2D and 34 healthy people
2018Pretorius et al., Parkinson's diseasePLoS ONEFibrin amyloid state seen in Parkinson's plasma and reversed by LBP in vitroLab study, 26 with Parkinson's and 19 healthy people
2020Pretorius et al., COVID-19 and T2DMCardiovasc DiabetolMicroclots in native plasma, higher in COVID-19 than in T2DMPreliminary report, 20 COVID-19, 10 T2DM, 10 healthy
2021Grobbelaar et al., spike protein S1Biosci RepSpike S1 added to healthy plasma altered fibrin(ogen) and resisted trypsin digestion; see spike and fibrinolysisIn vitro (lab dish)
2021Pretorius et al., Long COVIDCardiovasc DiabetolLarge amyloid deposits in Long COVID plasma, resistant to fibrinolysisObservational, 11 Long COVID, 15 acute COVID-19, 10 T2DM, 13 healthy
2022Kell, Laubscher and PretoriusBiochem JProposed a central role for microclots in Long COVID; see the research summaryReview and hypothesis
2022Nunes et al., ME/CFSPharmaceuticalsMicroclot area often over 10-fold greater than in controls, but lower than in Long COVID; see ME/CFS and microclotsObservational, 25 ME/CFS and 15 healthy
2023Turner et al., flow cytometryHeliyonImaging flow cytometry showed higher microclot concentration and size in Long COVIDObservational, 40 Long COVID and 20 healthy
2024Kell, Khan and PretoriusRes Pract Thromb HaemostReply to the Hunt et al. critiqueLetter
2025Thierry et al., NETsJ Med VirolNET markers were associated with microclot size and number; see microclots and NETsObservational

The pre-COVID row matters for the question "who discovered microclots". The 2016 to 2018 papers described amyloid-like fibrin before the pandemic. The COVID-19 and Long COVID papers applied the same staining approach. For what the particles are, see what microclots are and the Long COVID summary.

Next step

Want to see what's in your own blood sample?

Our at-home amyloid fibrin test uses Thioflavin T fluorescence microscopy and gives you a Videographic Microscopy Report to share with your doctor.

What does fibrinaloid mean?

Fibrinaloid means fibrin in an amyloid form. In their 2022 Biochemical Journal review, Kell, Laubscher and Pretorius wrote that, to avoid ambiguity, they considered it sensible to refer to such fibrin-based amyloids as fibrinaloids. We found no earlier use in Europe PMC, so "proposed in 2022" is the safe wording.

Who else has studied microclots?

A Liverpool group not led by Pretorius or Kell used the same Thioflavin T method on platelet-poor plasma. In Blood Advances in 2024, Schofield, Toh and colleagues studied 104 intensive care patients and 20 healthy controls. They found microclots in 44 patients (42.3%) at admission and in none of the controls, and they linked high counts to disseminated intravascular coagulation and 28-day mortality.

That study concerned critically ill patients, not Long COVID, and it used a staining method similar to Pretorius's. The 2025 NETs paper included Montpellier authors, as noted above.

Who disagrees, and why?

The 2023 Cochrane review (Fox, Hunt, Ariëns and colleagues) identified five laboratory studies. It reported particles in people with the condition, healthy people and people with diabetes, and judged the results insufficient to support an association with Long COVID. It found no randomised trials of plasmapheresis for this purpose.

Hunt and colleagues repeated that view in a 2024 editorial in Research and Practice in Thrombosis and Haemostasis, and Kell, Khan and Pretorius replied in the same journal. A further 2024 exchange of letters, with Connors and Ariëns responding to Kell and colleagues, carries a title that calls the roles of anticoagulation and microclots uncertain. We've read only the titles of those letters, so we don't summarise their arguments here. The wider debate is covered in are microclots real and microclots versus ordinary blood clots.

Can the public get tested through Pretorius's lab?

Her university work is research. Biocode Technologies, described in a Stellenbosch University article as a spin-out that licenses its microclot test to labs and clinics, lists bookings on its website that need the name of a referring doctor. For other options, see our directory of microclot testing labs and how microclots are tested. A treatment hypothesis from the same authors is covered in triple therapy for Long COVID; that decision belongs with your clinician.

Where does our test fit?

Our amyloid test uses the same staining principle, Thioflavin T fluorescence microscopy, as this published research. We have no affiliation with these researchers, and our dried finger-prick method has not been validated against their venous platelet-poor plasma method.

If you have sudden chest pain, severe breathlessness, one-sided weakness, confusion or a swollen painful leg, seek emergency care. These can signal a large clot or stroke, and no microclot result changes that.

Frequently asked questions

Who discovered microclots?

Researchers at Stellenbosch University and the University of Liverpool, led by Resia Pretorius and Douglas Kell, reported amyloid-like anomalous fibrin clotting in diseases such as type 2 diabetes from 2016. They described it in COVID-19 plasma in 2020 and in Long COVID in 2021. Other groups later used the same staining method, and critics dispute what the findings mean.

Who is Resia Pretorius?

Etheresia "Resia" Pretorius is a Distinguished Professor in Physiological Sciences at Stellenbosch University, South Africa, according to her ORCID record and a 2025 profile on The Conversation. A 2025 profile also lists her as Honorary Professor at the University of Liverpool. Her group studies how inflammatory molecules interact with clotting proteins, platelets and blood cells.

Who is Douglas Kell?

Douglas Kell is Research Chair in Systems Biology at the University of Liverpool, where he joined in December 2018, according to his university profile. He is a systems biologist who studied biochemistry at Oxford. He has co-authored most of the fibrin amyloid microclot papers with Pretorius, usually as senior or corresponding author.

What does fibrinaloid mean?

Fibrinaloid is shorthand for fibrin that has taken an amyloid form. Kell, Laubscher and Pretorius proposed it in a 2022 review to avoid ambiguity, writing that they considered it sensible to call these fibrin-based amyloids fibrinaloids. Fibrinaloid microclots and fibrin amyloid microclots are used for the same particles.

Does Resia Pretorius offer microclot testing to the public?

Testing in her university lab is research-based. A separate company, Biocode Technologies, a Stellenbosch University spin-out, lists microclot test bookings with a referring doctor on its website, including at Mediclinic Stellenbosch. Pretorius is named as a director of Biocode in a 2023 paper. For other options see our directory of labs and centres.

Sources

  1. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. Journal of The Royal Society Interface, 2016
  2. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017
  3. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovascular Diabetology, 2017
  4. Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease. PLoS ONE, 2018
  5. Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovascular Diabetology, 2020
  6. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Bioscience Reports, 2021
  7. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovascular Diabetology, 2021
  8. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal, 2022
  9. The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Pharmaceuticals, 2022
  10. Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model. Heliyon, 2023
  11. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database of Systematic Reviews, 2023
  12. Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality. Blood Advances, 2024
  13. Challenging the current hypothesis that thrombosis is responsible for the post-COVID-19 condition. Research and Practice in Thrombosis and Haemostasis, 2024
  14. Fibrinaloid microclots in long COVID: assessing the actual evidence properly. Research and Practice in Thrombosis and Haemostasis, 2024
  15. Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients. Journal of Medical Virology, 2025

At-Home Amyloid Test

Get Your Amyloid Test Kit Today

Simple at-home collection. Results in days.

    Next steps

    Tim Ottowitz

    Tim Ottowitz

    Founder & Research Lead

    Tim Ottowitz founded Amyloid Test and writes its Science Hub, turning fibrin amyloid and spike protein research into plain-language guides that stay close to the published evidence.

    Keep reading

    Illustration of red blood cells flowing through a blood vessel against a pale grid background
    Research
    Observational

    Amyloid Microclots: What the Research Shows So Far

    What studies show about amyloid microclots in Long COVID: how fibrin forms them, why they resist breakdown, the key findings and the open questions.

    Tim OttowitzApr 15, 2026
    6m
    Abstract illustration of red blood cells flowing through a translucent blood vessel on a pale background
    Guide
    Review

    Are Microclots Real? The Evidence For and Against

    Are microclots real? A two-sided review of what several labs have seen, what the 2023 Cochrane review and other critics dispute, and what remains unproven.

    Tim OttowitzNov 18, 2026
    8m
    Diagram of how a blood clot forms in a broken vessel, from platelet plug to fibrin mesh
    Guide
    Review

    Do Microclots Go Away? What the Research Does and Doesn't Show

    Do microclots go away? No study has followed untreated people over time, so no timeline exists. Here's how clots clear and what the data allows.

    Tim OttowitzNov 18, 2026
    7m